Pfizer Inc.'s first-quarter profit fell 19 percent, because of legal and other charges and new generic competition to blockbuster cholesterol pill Lipitor that cut the drugmaker's U.S. sales by 15 percent.
The world's biggest drugmaker beat Wall Street's profit expectations but narrowly missed its sales forecast in the first full quarter since Lipitor lost U.S. patent protection.
[See also: 5 best-selling drugs coming off patent]
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
